Novel nasal COVID-19 vaccine offers longer, better immunity than jabs
A nasal COVID-19 vaccine developed at Duke-NUS Medical School in Singapore is showing real promise: in hamster studies, it produced more central memory T cells than standard injections, hinting at protection that could last considerably longer. By delivering the vaccine right where the virus enters the body, researchers also saw stronger antibody responses against newly emerging variants. The team has filed a patent that covers other respiratory pathogens too, opening doors for future flu and RSV vaccines. Human trials are still ahead, but for anyone weary of frequent boosters — especially elderly and immunocompromised people — a needle-free shot offering broader, longer protection could meaningfully reshape how the world lives alongside evolving respiratory viruses.
